GentiBio
Latest round
- Series A
Last raised
- Aug 2021
Total raised
- $177M
Investors
- 7
About GentiBio
Based in Massachusetts, US, and founded in 2020 by co-founders Adel Nada, Andy Walker, and Chandra Patel. GentiBio, Inc. operates as a biotherapeutics company that develops engineered regulatory T cells to treat autoimmune allergic diseases. In August 2021, GentiBio, Inc. The company offers Tregs that operates a central role in keeping the immune system in check by combining insights from Tregs biology and antigen receptor engineering that enable the treatment of autoimmune, alloimmune, auto-inflammatory, and allergic diseases. GentiBio, Inc. In the year 2021, GentiBio is currently selecting its clinical candidate for T1D and will begin IND-enabling studies before the end of 2021.
Who invested in GentiBio
7 investors across 2 rounds
See all investors in GentiBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about GentiBio
Who invested in GentiBio?
GentiBio has 7 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has GentiBio raised?
GentiBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did GentiBio last raise money?
GentiBio's most recent round on record is a Series A, in Aug 2021.
What does GentiBio do?
Based in Massachusetts, US, and founded in 2020 by co-founders Adel Nada, Andy Walker, and Chandra Patel.
Where is GentiBio headquartered?
GentiBio is headquartered in Cambridge, US.
Which VCs invest in companies like GentiBio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at GentiBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like GentiBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.